G
Grace Cherry
Researcher at University of California, Los Angeles
Publications - 11
Citations - 10945
Grace Cherry is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Pembrolizumab & Melanoma. The author has an hindex of 8, co-authored 9 publications receiving 8264 citations.
Papers
More filters
Journal ArticleDOI
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh,Christina L. Harview,Jennifer H. Yearley,I. Peter Shintaku,Emma Taylor,Lidia Robert,Bartosz Chmielowski,Marko Spasic,Gina Henry,Voicu Ciobanu,Alisha N. West,Manuel Carmona,Christine Kivork,Elizabeth Seja,Grace Cherry,Antonio Gutierrez,Tristan Grogan,Christine Mateus,Gorana Tomasic,John A. Glaspy,Ryan O. Emerson,Harlan Robins,Robert H. Pierce,David Elashoff,Caroline Robert,Antoni Ribas +25 more
TL;DR: It is shown that pre-existing CD8+ T cells distinctly located at the invasive tumour margin are associated with expression of the PD-1/PD-L1 immune inhibitory axis and may predict response to therapy.
Journal ArticleDOI
Genomic and transcriptomic features of response to anti-pd-1 therapy in metastatic melanoma
Willy Hugo,Jesse M. Zaretsky,Lu Sun,Chunying Song,Blanca Homet Moreno,Siwen Hu-Lieskovan,Beata Berent-Maoz,Jia Pang,Bartosz Chmielowski,Grace Cherry,Elizabeth Seja,Shirley H. Lomeli,Xiangju Kong,Mark C. Kelley,Jeffrey A. Sosman,Douglas B. Johnson,Antoni Ribas,Roger S. Lo +17 more
TL;DR: It is found that overall high mutational loads associate with improved survival, and tumors from responding patients are enriched for mutations in the DNA repair gene BRCA2, suggesting that attenuating the biological processes that underlie IPRES may improve anti-PD-1 response in melanoma and other cancer types.
Journal ArticleDOI
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky,Angel Garcia-Diaz,Daniel Sanghoon Shin,Helena Escuin-Ordinas,Willy Hugo,Siwen Hu-Lieskovan,Davis Y. Torrejon,Gabriel Abril-Rodriguez,Salemiz Sandoval,Lucas Barthly,Justin Saco,Blanca Homet Moreno,Riccardo Mezzadra,Bartosz Chmielowski,Kathleen Ruchalski,I. Peter Shintaku,Phillip J. Sanchez,Cristina Puig-Saus,Grace Cherry,Elizabeth Seja,Xiangju Kong,Jia Pang,Beata Berent-Maoz,Begoña Comin-Anduix,Thomas G. Graeber,Paul C. Tumeh,Ton N. Schumacher,Roger S. Lo,Antoni Ribas +28 more
TL;DR: Acquired resistance to PD-1 blockade immunotherapy in patients with melanoma was associated with defects in the pathways involved in interferon-receptor signaling and in antigen presentation.
Journal ArticleDOI
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
Daniel Sanghoon Shin,Jesse M. Zaretsky,Helena Escuin-Ordinas,Angel Garcia-Diaz,Siwen Hu-Lieskovan,Anusha Kalbasi,Catherine S. Grasso,Willy Hugo,Salemiz Sandoval,Davis Y. Torrejon,Nicolaos Palaskas,Gabriel Abril Rodriguez,Giulia Parisi,Ariel M. Azhdam,Bartosz Chmielowski,Grace Cherry,Elizabeth Seja,Beata Berent-Maoz,I. Peter Shintaku,Dung Thi Le,Drew M. Pardoll,Luis A. Diaz,Paul C. Tumeh,Thomas G. Graeber,Roger S. Lo,Begoña Comin-Anduix,Antoni Ribas +26 more
TL;DR: It is proposed that JAK1/2 loss-of-function mutations are a genetic mechanism of lack of reactive PD-L1 expression and response to interferon gamma, leading to primary resistance to PD-1 blockade therapy.
Journal ArticleDOI
Erratum: Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma (Cell (2016) 165(1) (35–44)(S009286741630215X)(10.1016/j.cell.2016.02.065))
Willy Hugo,Jesse M. Zaretsky,Lu Sun,Chunying Song,Blanca Homet Moreno,Siwen Hu-Lieskovan,Beata Berent-Maoz,Jia Pang,Bartosz Chmielowski,Grace Cherry,Elizabeth Seja,Shirley H. Lomeli,Xiangju Kong,Mark C. Kelley,Jeffrey A. Sosman,Douglas B. Johnson,Antoni Ribas,Roger S. Lo +17 more